Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
821-840 of 1,738 trials

HIV Treatment: Combination Therapy Study

We are investigating a combination of three drugs to see if they can help reactivate HIV in people living with the virus. This study aims to understand the safety and effectiveness of these treatments.

HIV-1≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal Medicine

Solid Tumors: NECVAX-NEO1 with PD-1/PD-L1 Therapy

We are studying a new treatment, NECVAX-NEO1, for patients with solid tumors already on PD-1 or PD-L1 therapy. The trial aims to assess its safety and how well it may work in combination with existing treatments.

Advanced Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Celiac Disease: Amlitelimab Treatment Study

We are investigating whether amlitelimab can help adults with non-responsive celiac disease improve their symptoms and intestinal health while on a gluten-free diet. The study also examines the safety of this new treatment.

Coeliac Disease6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Parkinson’s Disease and Multiple System Atrophy: Exidavnemab Study

We are testing the safety and tolerability of a new treatment called exidavnemab in patients with Parkinson’s disease and Multiple System Atrophy. This study will help us understand how well different doses are accepted by patients.

Parkinson's DiseaseMultiple System Atrophy6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteNeurology

THEO-260 for Ovarian Cancer Treatment

We are studying a new treatment for patients with high-grade serous or endometrioid ovarian cancer to see if it is safe and effective. This trial will help us understand the best dose and how well it works compared to existing options.

Ovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Atopic Dermatitis: APG777 Treatment Study

We are studying a new treatment called APG777 for people with moderate-to-severe atopic dermatitis. The goal is to see if it helps reduce symptoms like itching and skin pain compared to a placebo.

Atopic Dermatitis>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Glioblastoma: Meclofenamate with Temozolomide

We are studying whether adding meclofenamate to standard temozolomide therapy helps patients with progressive MGMT-methylated glioblastoma. The trial will assess safety, effectiveness, and quality of life improvements.

Glioblastoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Non-Small Cell Lung Cancer: Sotorasib Treatment Study

We are studying the effects of Sotorasib in patients with non-operable non-small cell lung cancer who have a KRAS mutation. The goal is to see if this treatment improves survival and response rates compared to standard options.

Stage III Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Anti-CD19 CAR T-Cell Therapy for Autoimmune Diseases

We are studying a new treatment for people with active B-driven autoimmune diseases like lupus and scleroderma. The trial aims to evaluate its safety and initial effectiveness in managing these conditions.

Refractory Systemic Autoimmune Diseases3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Myelofibrosis: Selinexor Treatment Study

We are studying the effects of selinexor in patients with myelofibrosis who haven't been treated with JAK inhibitors. The goal is to see if it helps improve symptoms and overall health.

MyelofibrosisModerate ThrombocytopeniaEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Amyotrophic Lateral Sclerosis: ARGX-119 Study

We are testing a new treatment called ARGX-119 for adults with ALS to see if it is safe and how well it works in slowing disease progression.

Amyotrophic Lateral Sclerosis (ALS)>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Tafasitamab for Pediatric Acute B Lineage Leukemia

We are studying a new treatment for children with relapsed or refractory acute B lineage leukemia to see if it can help delay disease relapse and improve survival rates.

Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyPediatrics

Oral Propranolol for Preventing Eye Issues in Premature Infants

We are studying whether oral propranolol can help extremely preterm infants lower their risk of developing threshold retinopathy of prematurity. This research aims to improve safety and reduce the need for additional treatments.

Retinopathy of Prematurity>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteOphthalmologyPediatrics

Hearing Loss in Children: DB-OTO Gene Therapy

We are testing a new gene therapy for children and infants with hearing loss due to specific genetic mutations. The study aims to see if it is safe and effective in improving their hearing and speech skills.

Congenital Hearing Loss1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOtolaryngologyPediatrics

Cobolimab and Dostarlimab for Pediatric Tumors

We are studying a combination of two medications for children and young adults with newly diagnosed or relapsed solid tumors. The goal is to evaluate safety and how well it may work against specific cancers.

Hepatic CancerRhabdomyosarcomaGlioma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyPediatrics

Crohn's Disease: EXL01 for Post-Surgery Recurrence Prevention

We are studying whether EXL01 can help prevent the return of Crohn's disease in patients after surgery. This trial compares its effects to a placebo to assess safety and effectiveness.

Crohn's Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteGastroenterologyInternal Medicine

Sasanlimab for Muscle Invasive Bladder Cancer

We are studying whether sasanlimab can help patients with muscle invasive bladder cancer keep their bladder intact after initial treatment. The trial looks at survival rates and quality of life for participants.

Invasive Bladder Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Glycopyrronium for Asthma in Children

We are studying how well glycopyrronium works for children aged 6 to under 12 with asthma. The trial will also look at its safety and any side effects.

Asthma3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPediatricsPulmonology

Community-Acquired Pneumonia: Inhaled Levofloxacin Study

We are investigating whether inhaling levofloxacin helps improve health in patients with community-acquired pneumonia. This study includes individuals with and without pre-existing lung disease.

Community-acquired Pneumonia>2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesInfectious DiseasesPulmonology

Metastatic Breast Cancer: New HER2 Imaging Test

We are studying a new imaging method using 68Ga-ABS011 to see how well it detects HER2 status in metastatic breast cancer and other solid tumors. This may help improve diagnosis and treatment management.

Metastatic Breast Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineOncology